Jump Financial LLC purchased a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 15,767 shares of the company’s stock, valued at approximately $930,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Nisa Investment Advisors LLC acquired a new stake in shares of Progyny during the second quarter worth $38,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of Progyny during the first quarter worth $39,000. Altshuler Shaham Ltd acquired a new stake in shares of Progyny during the first quarter worth $42,000. Eaton Vance Management acquired a new stake in shares of Progyny during the first quarter worth $50,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Progyny during the first quarter worth $55,000. Hedge funds and other institutional investors own 85.05% of the company’s stock.
PGNY opened at $58.35 on Thursday. The firm has a 50-day moving average price of $55.00 and a 200-day moving average price of $55.62. Progyny, Inc. has a twelve month low of $23.56 and a twelve month high of $66.61. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of 74.81 and a beta of 1.78.
In other Progyny news, EVP Jennifer Bealer sold 1,930 shares of Progyny stock in a transaction that occurred on Friday, July 23rd. The shares were sold at an average price of $56.40, for a total transaction of $108,852.00. Following the completion of the sale, the executive vice president now directly owns 92,718 shares in the company, valued at $5,229,295.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Peter Anevski sold 27,539 shares of the business’s stock in a transaction that occurred on Thursday, October 7th. The stock was sold at an average price of $59.53, for a total transaction of $1,639,396.67. The disclosure for this sale can be found here. Insiders sold 529,004 shares of company stock valued at $29,735,046 over the last 90 days. 19.40% of the stock is owned by company insiders.
Several research analysts recently issued reports on PGNY shares. Berenberg Bank started coverage on shares of Progyny in a research note on Thursday, September 30th. They set a “buy” rating and a $81.00 target price on the stock. SVB Leerink cut their target price on shares of Progyny from $64.00 to $59.00 and set an “outperform” rating on the stock in a research note on Friday, August 6th. Barclays raised their price objective on shares of Progyny from $72.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, September 28th. Finally, Zacks Investment Research lowered shares of Progyny from a “buy” rating to a “hold” rating in a research note on Thursday, October 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $65.40.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Article: What is a stock portfolio tracker?
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.